Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 5/2023

Inhalt (23 Artikel)

Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis

  • Open Access
  • Review

Ádám Széles, Tamás Fazekas, Szilard Váncsa, Melinda Váradi, Petra Terézia Kovács, Ulrich Krafft, Viktor Grünwald, Boris Hadaschik, Anita Csizmarik, Péter Hegyi, Alex Váradi, Péter Nyirády, Tibor Szarvas

Local immunotherapy with the RNA-based immune stimulator CV8102 induces substantial anti-tumor responses and enhances checkpoint inhibitor activity

  • Open Access
  • Research

Johannes Lutz, Michael Meister, Mohamed Habbeddine, Katja Fiedler, Aleksandra Kowalczyk, Regina Heidenreich

Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy

  • Research

Cleopatra Rutihinda, Ryma Haroun, Nour Elhouda Saidi, Juan Pablo Ordoñez, Sahar Naasri, Dominique Lévesque, François-Michel Boisvert, Pierre-Hugues Fortier, Mathieu Belzile, Laurent Fradet, Vincent Hubert-Tremblay, Guy Anne Turgeon, Chang Shu Wang, Patrick Delage, Étienne Rousseau, Benoît Paquette, Ayman J. Oweida

Immunotherapy for lung cancer combining the oligodeoxynucleotides of TLR9 agonist and TGF-β2 inhibitor

  • Research

Yunpeng Yao, Jianhua Li, Kuo Qu, Yangeng Wang, Zhe Wang, Wenting Lu, Yongli Yu, Liying Wang

Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells

  • Open Access
  • Research

Alistair L. J. Symonds, Tizong Miao, Zabreen Busharat, Suling Li, Ping Wang

Generation of NK cells with chimeric-switch receptors to overcome PD1-mediated inhibition in cancer immunotherapy

  • Open Access
  • Research

Katharina H. Susek, Ysabel A. Schwietzer, Maria Karvouni, Mari Gilljam, Marton Keszei, Alamdar Hussain, Johan Lund, Muhammad Kashif, Andreas Lundqvist, Hans-Gustaf Ljunggren, Hareth Nahi, Arnika K. Wagner, Evren Alici

Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model

  • Open Access
  • Research

Tianyun Qiao, Jinbo Zhao, Xiangbing Xin, Yanlu Xiong, Wenwen Guo, Fancheng Meng, Hui Li, Yangbo Feng, Hui Xu, Changhong Shi, Yong Han

Correction to: Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model

  • Open Access
  • Correction

Tianyun Qiao, Jinbo Zhao, Xiangbing Xin, Yanlu Xiong, Wenwen Guo, Fancheng Meng, Hui Li, Yangbo Feng, Hui Xu, Changhong Shi, Yong Han

Novel ocular immunotherapy induces tumor regression in an equine model of ocular surface squamous neoplasia

  • Research

Kathryn L. Wotman, Lyndah Chow, Brittany Martabano, Lynn M. Pezzanite, Steven Dow

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy

  • Open Access
  • Research

Yun Gu, Puran Zhang, Jieti Wang, Chao Lin, Hao Liu, He Li, Hongyong He, Ruochen Li, Heng Zhang, Weijuan Zhang

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

  • Open Access
  • Research

Andrea Knight, Martin Piskacek, Michal Jurajda, Jirina Prochazkova, Zdenek Racil, Daniela Zackova, Jiri Mayer

Nonlinear association between body mass index and overall survival in advanced NSCLC patients treated with immune checkpoint blockade

  • Research

Aditya Jain, Shijia Zhang, Ryan M. Shanley, Naomi Fujioka, Robert A. Kratzke, Manish R. Patel, Amit A. Kulkarni

Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model

  • Open Access
  • Research

Jaya Lakshmi Thangaraj, Sung-Hoon Jung, Manh-Cuong Vo, Tan-Huy Chu, Minh-Trang Thi Phan, Kyung-Hwa Lee, Seo-Yeon Ahn, Mihee Kim, Ga-Young Song, Jae-Sook Ahn, Deok-Hwan Yang, Hyeoung-Joon Kim, Duck Cho, Je-Jung Lee

Improved MAIT cell functions following fecal microbiota transplantation for metastatic renal cell carcinoma

  • Research

Marina Ninkov, Crystal L. Schmerk, Manoosh Moradizadeh, Seema N. Parvathy, Rene Figueredo, Jeremy P. Burton, Michael S. Silverman, Ricardo Fernandes, Saman Maleki Vareki, S. M. Mansour Haeryfar

Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial

  • Research

Cunte Chen, Siyang Maggie Liu, Yedan Chen, Qiuxiang Ou, Hua Bao, Ling Xu, Yikai Zhang, Jia-Tao Zhang, Wenzhao Zhong, Qing Zhou, Xue-Ning Yang, Yang Shao, Yi-Long Wu, Si-Yang Liu, Yangqiu Li

Senescence-associated secretory proteins induced in lung adenocarcinoma by extended treatment with dexamethasone enhance migration and activation of lymphocytes

  • Research

Prahlad Parajuli, Rayna Rosati, Hirva Mamdani, Robert E. Wright III, Zahin Hussain, Aroma Naeem, Sijana Dzinic, Lisa Polin, Navnath S. Gavande, Manohar Ratnam

Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer

  • Research

Yoshinori Kajiwara, Hiroshi Tazawa, Motohiko Yamada, Nobuhiko Kanaya, Takuro Fushimi, Satoru Kikuchi, Shinji Kuroda, Toshiaki Ohara, Kazuhiro Noma, Ryuichi Yoshida, Yuzo Umeda, Yasuo Urata, Shunsuke Kagawa, Toshiyoshi Fujiwara

Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells

  • Research

Sizhen Wang, Xiaohui Zhang, Xuemei Zou, Maorong Wen, Chi Gan, Xiaochun Jiang, Min Li, Rongxi Shen, Daojun Zhu, Anlong Yao, Yu Fang, Bernard A. Fox, Hong-Ming Hu, Guangjie Yu, Xinbo Wang

Brief report: STING expressed in tumor and non-tumor compartments has distinct roles in regulating anti-tumor immunity

  • Open Access
  • Brief Report

Jennie C. Kim, Xian Liu, Karen Fitzgerald, Jason S. Eng, Jessica Orf, Sarah A. O’Brien, Brian Belmontes, Amy-Jo Casbon, Sergey V. Novitskiy, Kristin V. Tarbell, Jason DeVoss, Jackson G. Egen

Correction to: Let‑7d inhibits intratumoral macrophage M2 polarization and subsequent tumor angiogenesis by targeting IL‑13 and IL‑10

  • Correction

Boxing Su, Haibo Han, Yanqing Gong, Xuesong Li, Chaoyue Ji, Jingjing Yao, Jianghui Yang, Weiguo Hu, Wei Zhao, Jianxing Li, Gang Zhang, Liqun Zhou

Correction to: TIGIT blockade enhances tumor response to radiotherapy via a CD103 + dendritic cell-dependent mechanism

  • Open Access
  • Correction

Kaikai Zhao, Liyang Jiang, Youjiao Si, Shujie Zhou, Zhaoqin Huang, Xiangjiao Meng

Neu im Fachgebiet Onkologie

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Weniger aggressive Prostatakrebs-Therapie, gleiche Prognose

Erhalten ältere Prostatakrebs-Patienten vor Therapiebeginn ein geriatrisches Assessment, führt dies häufig zu einer Deeskalation der Behandlung – ohne dass ihre Prognose dadurch schlechter würde. Darauf deuten Erfahrungen aus Frankreich hin. 

Nach kardiovaskulärer Erkrankung steigt das Krebsrisiko

Wer an einer kardiovaskulären Erkrankung (CVD) leidet, hat offenbar ein erhöhtes Risiko, in der Folge auch noch eine Krebsdiagnose zu erhalten. Der Zusammenhang scheint für diverse CVD und Krebsentitäten zu gelten.

Fortgeschrittenes Melanom: Wann den Checkpoint-Inhibitor absetzen?

Eine ICI-Therapie sollte bei Betroffenen mit fortgeschrittenem Melanom mindestens ein Jahr fortgesetzt werden. Bei anhaltendem Ansprechen kann danach offenbar ohne hohes Risiko ein Therapieabbruch erwogen werden.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.